# EDGAR Filing Document

**Accession Number:** 0001876431
**File Stem:** 0001628280-26-034812
**Filing Date:** 2026-5
**Character Count:** 10754
**Document Hash:** 2e84e384c3d0154e45cee031a7c862be
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-034812.hdr.sgml**: 20260514

**ACCESSION NUMBER**: 0001628280-26-034812

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260514

**FILED AS OF DATE**: 20260514

**DATE AS OF CHANGE**: 20260514

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Prenetics Global Ltd
- **CENTRAL INDEX KEY:** 0001876431
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41401
- **FILM NUMBER:** 26975951

**BUSINESS ADDRESS:**
- **STREET 1:** 7/F, K11 ATELIER, 728 KING'S ROAD
- **CITY:** QUARRY BAY
- **STATE:** K3
- **ZIP:** 000000
- **BUSINESS PHONE:** (852) 2210-7188

**MAIL ADDRESS:**
- **STREET 1:** 7/F, K11 ATELIER, 728 KING'S ROAD
- **CITY:** QUARRY BAY
- **STATE:** K3
- **ZIP:** 000000

**UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE<br>13a-16 OR 15d-16 UNDER<br>THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of May 2026**

**Commission File Number 001-41401** 

**Prenetics Global Limited**

**Unit 703-706, K11 Atelier**<br>**728 King's Road, Quarry Bay** <br>**Hong Kong**<br>

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

------

**EXPLANATORY NOTE**

On May 14, 2026, Prenetics Global Limited (the "Company") issued a press release announcing the appointment of Brian J. Rosin as Chief Financial Officer of IM8. A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

**EXHIBIT INDEX**

Exhibit No. Description <br> 99.1 <u>[Press Release - Prenetics Welcomes Brian J. Rosin as Chief Financial Officer of IM8](im8cfoannouncement140526_f.htm)</u>

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **Prenetics Global Limited** | **Prenetics Global Limited** |
| | By: | /s/ Danny Sheng Wu Yeung |
| | Name: | Danny Sheng Wu Yeung |
| | Title: | Chief Executive Officer |
| Date: May 14, 2026 |  |  |

---

## Exhibit 99.1

**Prenetics Welcomes Brian J. Rosin as Chief Financial Officer of IM8**

*~ Two-decade veteran of premium consumer health, nutrition, and direct-to-consumer brands joins IM8 to support its rapid global expansion*

**NEW YORK, N.Y., May 14, 2026 (GLOBE NEWSWIRE) –** Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced the appointment of Brian J. Rosin as Chief Financial Officer of IM8. Mr. Rosin will be based in the United States and will lead finance organization, reporting to Chief Executive Officer Danny Yeung. Mr. Rosin's appointment establishes dedicated finance leadership for IM8 to support the Company's growing operations and the rapid global expansion of the IM8 brand.

Mr. Rosin brings nearly two decades of financial leadership in consumer e-Commerce and premium wellness subscription brands, with significant transaction experience including several successful exits. He joins IM8 at a pivotal moment, as IM8 has become one of the fastest growing supplement brands ever recorded in the industry, is now sold in more than 40 countries, and is projecting $190 million to $210 million in revenue for full year 2026 in just its second year from launch.

In his new role, Mr. Rosin will be responsible for financial strategy, capital allocation, investor relations support, and the financial infrastructure and unit-economics discipline required to scale a premium consumer health brand from breakout launch to durable, profitable, global category leadership.

**Danny Yeung, Co-Founder and Chief Executive Officer of Prenetics, commented:** "Brian's entire career has been spent at the intersection of high growth consumer, premium nutrition, and subscription supplements in e-Commerce. He understands the unit economics, brand-building discipline, and operating cadence required to turn a breakout consumer health product into an enduring, global category leader. As IM8 expands across more than 40 countries and into new daily nutrition formats, Brian's expertise will be invaluable in ensuring the financial discipline and infrastructure behind our growth match the ambition of the brand."

**Brian J. Rosin, Chief Financial Officer of IM8, commented:** "I've spent nearly two decades helping build premium consumer health brands, and what drew me to IM8 was the data — the unit economics and retention here are unlike anything I've seen in the category. David Beckham as a co-founding partner, world-class athletes as authentic users, science-backed formulations, and an AI-native operating culture make for a rare platform in consumer health. I'm honored to join Danny and the team, and I look forward to building the financial foundation to support IM8's next phase of growth in the United States and globally."

Mr. Rosin joins IM8 from Wellbeam Consumer Health, a private equity-backed e-Commerce-focused consumer wellness platform, where he served as Chief Financial Officer and Senior Vice President, e-Commerce Operations. In those roles, he led finance and digital commerce across Wellbeam's portfolio of brands, including TruSkin (clean, plant-powered skincare), BioTRUST Nutrition (direct-to-consumer nutrition for healthy aging), Eu Natural (women's botanical supplements), and Penetrex (joint and muscle therapy, divested in 2024). He originally joined TruSkin as CFO in 2020, prior to its acquisition by Wellbeam in 2021. Earlier in his career, he also held CFO roles at NATURELO Premium Supplements, and Rant, Inc. Mr. Rosin holds dual bachelor's degrees, Cum Laude, in Economics and Political Science from Northern Illinois University.

**About IM8**

IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. IM8's flagship product, Daily Ultimate Essentials Pro, is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and

------

contains no artificial flavors, colors or sweeteners. IM8 is trusted by NBA Champion and two-time MVP Giannis Antetokounmpo, World No. 1 tennis player Aryna Sabalenka, and F1 driver Ollie Bearman. Since its launch, IM8 has become one of the fastest-growing brands in consumer health, surpassing $100 million in annualized recurring revenue within just 11 months and is now sold in more than 40 countries worldwide. IM8 is a subsidiary of Prenetics (NASDAQ: PRE). To learn more, visit www.IM8health.com.

**About Prenetics**

Prenetics (NASDAQ: PRE) is a leading health sciences company dedicated to advancing human health and longevity. The Company's flagship consumer brand, IM8, co-founded with David Beckham and trusted by NBA superstar Giannis Antetokounmpo, World No. 1 tennis player Aryna Sabalenka and F1 phenom Ollie Bearman, is redefining the premium daily nutrition category through science-backed formulations and global brand partnerships. Since its launch, IM8 has become one of the fastest-growing brands in consumer health, achieving an impressive milestone of surpassing $100 million in annualized recurring revenue within just 11 months of operations, and is now sold in more than 40 countries worldwide.

**Investor Relations Contact**

investors@prenetics.com

PRE@mzgroup.us

Angela Cheung

Investor Relations / Corporate Finance

angela.hm.cheung@prenetics.com

------

**Forward-Looking Statements**

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. Our guidance reflects management's current estimates and assumptions as of the date of this release, is subject to significant risks and uncertainties, and is not a guarantee of future performance. Actual results may differ materially. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to," "guidance," "outlook," "forecast," or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, and therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: the Company may not be able to maintain and enhance its IM8 business and brand if it suffers negative publicity or fails to maintain a strong base of engaged customers and content creators, or otherwise fails to meet customers' expectations; the Company's ability to further develop and grow its business, including new products and services; and its ability to identify and execute on M&A opportunities. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the "Risk Factors" section of the Company's most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. Unless otherwise specified, all information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law. Nothing in this press release constitutes an offer to sell, or the solicitation of an offer to buy, any securities of the Company.

<br>